Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, multi-centre study to evaluate the safety and efficacy of tetradecanoylphorbol acetate in patients with acute myelocytic leukemia and myelodysplastic syndrome

Next Previous
Trial Profile

A phase II, multi-centre study to evaluate the safety and efficacy of tetradecanoylphorbol acetate in patients with acute myelocytic leukemia and myelodysplastic syndrome

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tetradecanoylphorbol acetate (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 31 May 2017 According to a Rich Pharmaceuticals media release, the company has filed its submission package to the Institutional Review Board (IRB) of Phramongkutklao Hospital in Bangkok.
    • 31 May 2017 According to a Rich Pharmaceuticals media release, the company is preparing submission packages for the Hospital's Internal Review Board (IRB) and the Thailand Food and Drug Administration (FDA). This package is near completion and the Company plans to submit it shortly.
    • 16 Feb 2016 According to Rich Pharmaceuticals media release, company is planning to enrol patients from the US and Thailand.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top